Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.40 |
| ▸ | CHRNG | P07510 | 4/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.40 |
| ▸ | CHRND | Q07001 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289160 | 1.00 | SLC6A3 (0.44) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL43590 | 1.00 | SLC6A3 (0.44) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1716976 | 1.00 | SLC6A3 (0.44) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Hydrochloric Acid SCHEMBL29399049 | 0.97 | SLC6A3 (0.42) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Hydrochloric Acid SCHEMBL8190787 | 0.97 | SLC6A3 (0.42) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Hydrochloric Acid SCHEMBL8190786 | 0.97 | SLC6A3 (0.42) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2946675 | 0.85 | SLC6A3 (0.36) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2946672 | 0.85 | SLC6A3 (0.36) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL24766215 | 0.84 | MME (0.48) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL20677212 | 0.84 | MME (0.48) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12320 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606594-B2 | Heterotandem bicyclic peptide complexes | BICYCLETX LIMITED (GB) | 2026-04-21 | — | — | US | claimed |
| US-20250340595-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | BICYCLETX LTD (GB) | 2025-11-06 | — | — | US | claimed |
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLE TX LTD (GB) | 2025-10-23 | — | — | US | claimed |
| US-12435107-B2 | Heterotandem bicyclic peptide complex | BICYCLETX LIMITED (GB) | 2025-10-07 | — | — | US | claimed |
| US-12428447-B2 | Peptide-based non-proteinaceous cargo delivery | FELDAN BIO INC. (CA) | 2025-09-30 | — | — | US | claimed |
| US-12378288-B2 | Multimeric bicyclic peptide ligands | BICYCLETX LIMITED (GB) | 2025-08-05 | — | — | US | claimed |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2025-06-17 | — | — | US | claimed |
| US-20250186539-A2 | METHODS FOR TREATING CANCER | BICYCLETX LIMITED (GB) | 2025-06-12 | — | — | US | claimed |
| WO-2025120217-A2 | NOVEL POLYPEPTIDES | ONCOPEPTIDES INNOVATION 1 AB (SE) | 2025-06-12 | — | — | WO | claimed |
| WO-2025120219-A2 | NOVEL POLYPEPTIDES | ONCOPEPTIDES INNOVATION 1 AB (SE) | 2025-06-12 | — | — | WO | claimed |
| US-6232305-B1 | ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | NAEJA PHARMACEUTICAL INC. (CA) | 2001-05-15 | — | — | US | claimed |
| US-6194386-B1 | SELECTIVE AFFINITY TO NEUROTENSIN RECEPTORS, COMPARABLE WITH THAT OF NEUROTENSIN ITSELF, AND WHICH HAS SUFFICIENT ENZYMATIC RESISTANCE TO ALLOW ITS USE IN DIAGNOSIS AND THERAPY; RADIOACTIVE CHELATE PEPTIDES; IN VIVO STABILITY | MALLINCKRODT INC. | 2001-02-27 | — | — | US | claimed |
| EP-0725797-B1 | BIVALENT THROMBIN INHIBITORS | CA NAT RESEARCH COUNCIL (CA) | 2001-01-10 | — | — | EP | claimed |
| WO-2000078796-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | MALLINCKRODT INC. (US) | 2000-12-28 | — | — | WO | claimed |
| EP-0989136-A1 | PEPTIDES HAVING CYCLIC STRUCTURES AND EXERTING P53 PROTEIN ACTIVTY-RESTORING EFFECT ON P53 PROTEIN MUTANTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-03-29 | — | — | EP | claimed |
| US-5952464-A | OLIGOPEPTIDE WITH SELECTIVE NEUROTENSIN RECEPTOR AFFINITY LABELLED WITH METAL ISOTOPE OR RADIOACTIVE HALOGEN ISOTOPE; FOR DIAGNOSTIC IMAGING AND ANTICARCINOGENIC AGENTS | MALLINCKRODT INC. (US) | 1999-09-14 | — | — | US | claimed |
| US-5734018-A | BIOSYNTHESIS DETECTION, ANALYZING METHOD TO OBTAIN PEPTIDE SEQUENCES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 1998-03-31 | — | — | US | claimed |
| EP-0725797-A1 | BIVALENT THROMBIN INHIBITORS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1996-08-14 | — | — | EP | claimed |
| WO-1995011921-A1 | BIVALENT THROMBIN INHIBITORS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1995-05-04 | — | — | WO | claimed |
| EP-0242245-A2 | Chemiluminescence method for assaying compounds containing primary amino groups using 1-cyano-2-substituted benz(f)- or naphth(f)isoindole fluorescers | OREAD LABORATORIES, INC. (US) | 1987-10-21 | — | — | EP | claimed |